| Q52590498 | A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention |
| Q38911866 | A Systematic Review and Meta-Analysis on Self-Management for Improving Risk Factor Control in Stroke Patients |
| Q41620962 | Adequate Platelet Function Inhibition Confirmed by Two Inductive Agents Predicts Lower Recurrence of Ischemic Stroke/Transient Ischemic Attack. |
| Q40559692 | Adverse outcome after incident stroke hospitalization for Indigenous and non-Indigenous Australians in the Northern Territory. |
| Q91707571 | Aerobic Training and Mobilization Early Post-stroke: Cautions and Considerations |
| Q90106705 | Age disparity in diagnostic evaluation of stroke patients: Embolic Stroke of Undetermined Source Global Registry Project |
| Q92332755 | Anti-Platelet Therapy in Mild Cerebral Infarction Patients on the Basis of CYP2C19 Metabolizer Status |
| Q28076042 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis |
| Q38917775 | Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease |
| Q24646522 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke |
| Q41807386 | Association of carotid plaque echogenicity with recurrence of ischemic stroke |
| Q53227142 | Association of ischemic stroke to coronary artery disease using computed tomography coronary angiography |
| Q36979324 | Atorvastatin in prevention of stroke and transient ischaemic attack |
| Q41531044 | Biomarkers of Acute Stroke Etiology (BASE) Study Methodology. |
| Q37894582 | Blood lipids and stroke: what more can we do besides reducing low-density lipoprotein cholesterol? |
| Q34722888 | Blood-brain barrier alterations provide evidence of subacute diaschisis in an ischemic stroke rat model |
| Q36391560 | Bouncing-back: rehospitalization in patients with complicated transitions in the first thirty days after hospital discharge for acute stroke |
| Q64253243 | C-reactive protein for predicting all-cause mortality in patients with acute ischemic stroke: a meta-analysis |
| Q35968346 | Cardiovascular risk in survivors of stroke |
| Q27011252 | Case characteristics, hyperacute treatment, and outcome information from the clinical research center for stroke-fifth division registry in South Korea |
| Q37100539 | Changes in pre-hospital management of vascular risk factors among patients admitted due to recurrent stroke in Poland from 1995 to 2013. |
| Q79219462 | Cholesterol lowering to prevent stroke: who, when, and how? |
| Q89219565 | Clinical and Imaging Predictors of Recurrent Ischemic Stroke: A Systematic Review and Meta-Analysis |
| Q35210553 | Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension |
| Q34418099 | Clinicoradiological features of recurrent ischemic stroke: healthcare for poststroke patients |
| Q58123900 | Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data |
| Q41610186 | Comparison of Long-Term Clinical Outcomes after Drug-Eluting Stent Implantation in Patients with Coronary Artery Disease with and without Prior Cerebral Infarction |
| Q37244467 | Coronary risk stratification in patients with ischemic stroke or transient ischemic stroke attack. |
| Q37774894 | Current issues in antiplatelet therapy for stroke prevention: the importance of stroke subtypes and differences between stroke and MI patients |
| Q30595943 | Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients |
| Q88291496 | Drug therapy management in a pharmacist-run stroke prevention clinic |
| Q45147508 | Early recurrence of ischemic stroke in Japanese patients: the Japan standard stroke registry study |
| Q38027291 | Epidemiology and Risk Factors |
| Q38169038 | Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association |
| Q22306331 | Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association |
| Q64251156 | Home-based aerobic exercise in patients with lacunar stroke: Design of the HITPALS randomized controlled trial |
| Q37277220 | Identification and management of polyvascular disease in patients with noncardioembolic ischaemic stroke |
| Q62341493 | Impact of Delayed Transfer of Critically Ill Stroke Patients from the Emergency Department to the Neuro-ICU |
| Q52344578 | Impact of acute-phase complications and interventions on 6-month survival after stroke. A prospective observational study |
| Q97646612 | Inclusion of People Poststroke in Cardiac Rehabilitation Programs in Canada: A Missed Opportunity for Referral |
| Q34010411 | Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease |
| Q48720131 | Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study. |
| Q56979792 | Interactions Between Cardiovascular and Cerebrovascular Disease |
| Q48585907 | Intermediate risk of cardiac events and recurrent stroke after stroke admission in young adults |
| Q60045121 | Interventions for behaviour change and self-management in stroke secondary prevention: protocol for an overview of reviews |
| Q26851408 | Is there a consistent association between coronary heart disease and ischemic stroke caused by intracranial atherosclerosis? |
| Q98177046 | Lipoxins, RevD1 and 9, 13 HODE as the most important derivatives after an early incident of ischemic stroke |
| Q49590294 | Long-Term Outcome After Carotid Endarterectomy in Patients with Ischemic Heart Disease |
| Q49953435 | Long-Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta-Analysis |
| Q40109985 | Long-term morbidity and mortality in patients without early complications after stroke or transient ischemic attack |
| Q35145541 | Long-term prognosis and prognostic determinants of patients with first attack of mild and moderate ischemia at Beijing community hospitals |
| Q90665798 | Movement behavior remains stable in stroke survivors within the first two months after returning home |
| Q47908955 | Multifactorial analysis of factors affecting recurrence of stroke in Japan. |
| Q46569463 | Multilevel assessment of atherosclerotic extent using a 40-section multidetector scanner after transient ischemic attack or ischemic stroke. |
| Q35007367 | Neurogenic stunned myocardium |
| Q47680225 | No Racial Difference in Rehabilitation Therapy Across All Post-Acute Care Settings in the Year Following a Stroke |
| Q35268065 | Perception of recurrent stroke risk among black, white and Hispanic ischemic stroke and transient ischemic attack survivors: the SWIFT study |
| Q36483865 | Perioperative stroke |
| Q37465183 | Pharmacotherapy for the secondary prevention of stroke |
| Q36953272 | Pioglitazone after Ischemic Stroke or Transient Ischemic Attack |
| Q42379243 | Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials |
| Q34625239 | Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial |
| Q64102981 | Planning After Stroke Survival: Advance Care Planning in the Stroke Clinic |
| Q52152012 | Presence and extent of coronary calcified plaque evaluated by coronary computed tomographic angiography are independent predictors of ischemic stroke in patients with suspected coronary artery disease |
| Q33516386 | Primary end-point times, functional outcome and adverse event profile after acute ischaemic stroke |
| Q57040104 | Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality |
| Q89620648 | Rate and Determinants of Recurrence at 1 Year and 5 Years After Stroke in a Low-Income Population in Rural China |
| Q37362773 | Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes? |
| Q88962201 | Rheumatoid arthritis significantly increased recurrence risk after ischemic stroke/transient ischemic attack |
| Q38092043 | Role of cardiac and extracranial vascular CT in the evaluation/management of cerebral ischemia and stroke |
| Q39000216 | Role of hospitalists in the diagnosis of atrial fibrillation for the management of cryptogenic stroke patients |
| Q37599670 | Secondary prophylactic treatment and long-term prognosis after TIA and different subtypes of stroke. A 25-year follow-up hospital-based observational study |
| Q53825822 | Secondary stroke prevention services in Canada: a cross-sectional survey and geospatial analysis of resources, capacity and geographic access |
| Q35628136 | Self-reported stroke symptoms without a prior diagnosis of stroke or transient ischemic attack: a powerful new risk factor for stroke |
| Q37947405 | Should all patients at high cardiovascular risk receive renin-angiotensin system blockers? |
| Q64111672 | Six-Month Outcome of Transient Ischemic Attack and Its Mimics |
| Q37341721 | Statin Prescription Adhered to Guidelines for Patients Hospitalized due to Acute Ischemic Stroke or Transient Ischemic Attack |
| Q82382546 | Statins after recent stroke reduces recurrence and improves survival in an aging Mediterranean population without known coronary heart disease |
| Q37896071 | Telmisartan for the management of patients at high cardiovascular risk |
| Q39652230 | Temporal Trends in Risk of Future Cardiac Events among Stroke Survivors in the United States |
| Q35687241 | The ABCD and ABCD2 Scores and the Risk of Stroke following a TIA: A Narrative Review |
| Q64950572 | The Association of Serum Testosterone Levels With Recurrence and Mortality After Acute Ischemic Stroke in Males. |
| Q60921340 | The Impact of Ischaemic Stroke Subtype on 30-day Hospital Readmissions |
| Q35242566 | The inclusion of stroke in risk stratification for primary prevention of vascular events: the Northern Manhattan Study |
| Q35945462 | Tracking Stroke Hospitalization Clusters Over Time and Associations With County-Level Socioeconomic and Healthcare Characteristics |
| Q64073334 | Trends in the incidence of recurrent stroke at 5 years after the first-ever stroke in rural China: a population-based stroke surveillance from 1992 to 2017 |
| Q57243401 | Two-Year Vascular Event Rates in Patients with Symptomatic Cerebrovascular Disease: The REACH Registry |
| Q46794695 | Utility of Framingham Coronary Heart Disease Risk Score for Predicting Cardiac Risk After Stroke |
| Q38904060 | When a Single Antiplatelet Agent for Stroke Prevention Is Not Enough: Current Evidence and Future Applications of Dual Antiplatelet Therapy |
| Q37884204 | Why do ischemic stroke and transient ischemic attack patients get readmitted? |
| Q80721294 | [Statins in the secondary prevention of ictus in the community] |